Comera Life Sciences Holdings Inc

CMRA

NASDAQ. Currency in USD

1.47 -0.04 ( -2.65% )

Real time prices: December 06

Market Cap.
29.18M
Beta (5Y monthly)
-
Price/Earnings
-
EPS (TTM)
-0.94
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
27,660
1y Target Est.
0.00
Day's Range
1.47
-
1.58
52 Week's Range
1.11
-
11.44

Historical Summary

Performance
EPS growth
Share Buybacks

About Comera Life Sciences Holdings Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://comeralifesciences.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
16.41M
Employees
11
Address
12 Gill Street, Woburn, MA, United States, 01801
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Latest news

Comera Life Sciences to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
Comera Life Sciences to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA),...
By GlobeNewswire Inc. - 2 weeks ago

$1.5 Million Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
$1.5 Million Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones closed higher by over 400 points on Monday. Investors, meanwhile, focused on...
By Benzinga - 6 weeks ago

Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study

WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA),...
By GlobeNewswire Inc. - 7 weeks ago

Comera Life Sciences Expands Woburn Operations
Comera Life Sciences Expands Woburn Operations

Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event
By GlobeNewswire Inc. - 9 weeks ago

Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday

Gainers LAVA Therapeutics N.V. (NASDAQ: LVTX) shares climbed 97.5% to close at $4.74 on Monday...
By Benzinga - 10 weeks ago

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and...
By Benzinga - 10 weeks ago

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday....
By Benzinga - 11 weeks ago

Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session

Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11%...
By Benzinga - 11 weeks ago